MA32080B1 - Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1 - Google Patents

Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1

Info

Publication number
MA32080B1
MA32080B1 MA33087A MA33087A MA32080B1 MA 32080 B1 MA32080 B1 MA 32080B1 MA 33087 A MA33087 A MA 33087A MA 33087 A MA33087 A MA 33087A MA 32080 B1 MA32080 B1 MA 32080B1
Authority
MA
Morocco
Prior art keywords
rpe
optionally
response
vaccine
ribosomal protein
Prior art date
Application number
MA33087A
Other languages
Arabic (ar)
English (en)
Inventor
Manuel Soto Álvarez
Daniel Ruiz Abánades
Carlos Alonso Bedate
Original Assignee
Leti S L Unipersonal Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti S L Unipersonal Lab filed Critical Leti S L Unipersonal Lab
Publication of MA32080B1 publication Critical patent/MA32080B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition comprenant un rpe et facultativement un adjuvant promouvant la réponse th1 pour la préparation d'un médicament destiné au traitement ou à la prévention d'une maladie parasitaire, ainsi que son utilisation.
MA33087A 2008-01-18 2010-08-13 Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1 MA32080B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2192808P 2008-01-18 2008-01-18
EP08100634 2008-01-18
PCT/EP2009/050334 WO2009090175A1 (fr) 2008-01-18 2009-01-14 Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1

Publications (1)

Publication Number Publication Date
MA32080B1 true MA32080B1 (fr) 2011-02-01

Family

ID=39471089

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33087A MA32080B1 (fr) 2008-01-18 2010-08-13 Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1

Country Status (19)

Country Link
US (1) US20110020405A1 (fr)
EP (2) EP2570427A1 (fr)
JP (2) JP2011509968A (fr)
CN (1) CN101977930B (fr)
AP (1) AP3007A (fr)
AU (1) AU2009204849B2 (fr)
BR (1) BRPI0906787A2 (fr)
CA (1) CA2712475A1 (fr)
CO (1) CO6280495A2 (fr)
DK (1) DK2231700T3 (fr)
ES (1) ES2486365T3 (fr)
HR (1) HRP20140447T1 (fr)
MA (1) MA32080B1 (fr)
MX (1) MX2010007831A (fr)
PL (1) PL2231700T3 (fr)
PT (1) PT2231700E (fr)
RU (1) RU2521499C2 (fr)
WO (1) WO2009090175A1 (fr)
ZA (1) ZA201005143B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
CN103270048B (zh) 2010-11-10 2016-11-23 热体实验室有限公司 新型佐剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500437B1 (en) * 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ES2273519T3 (es) * 1998-12-23 2007-05-01 C.B.F. Leti S.A. Gen quimerico que codifica los determinantes antigenicos de cuatro proteinas de l. infantum.
ES2169995B1 (es) * 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20030072714A1 (en) * 2001-10-12 2003-04-17 Magill Alan J. Microfluidized leishmania lysate and methods of making and using thereof

Also Published As

Publication number Publication date
CN101977930A (zh) 2011-02-16
PT2231700E (pt) 2014-07-31
HRP20140447T1 (hr) 2014-07-04
US20110020405A1 (en) 2011-01-27
WO2009090175A1 (fr) 2009-07-23
AU2009204849A1 (en) 2009-07-23
BRPI0906787A2 (pt) 2015-08-18
AP3007A (en) 2014-10-31
CN101977930B (zh) 2014-12-17
CO6280495A2 (es) 2011-05-20
AU2009204849B2 (en) 2013-10-03
AP2010005333A0 (en) 2010-08-31
EP2231700A1 (fr) 2010-09-29
PL2231700T3 (pl) 2014-09-30
RU2010134427A (ru) 2012-02-27
JP2011509968A (ja) 2011-03-31
RU2521499C2 (ru) 2014-06-27
CA2712475A1 (fr) 2009-07-23
HK1150291A1 (en) 2011-11-18
EP2570427A1 (fr) 2013-03-20
MX2010007831A (es) 2011-06-20
EP2231700B1 (fr) 2014-05-07
ES2486365T3 (es) 2014-08-18
ZA201005143B (en) 2011-12-28
DK2231700T3 (da) 2014-07-14
JP2015180638A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
MA29714B1 (fr) Vaccin
MA28149A1 (fr) Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA30298B1 (fr) Composition
MA30866B1 (fr) Vaccin
MA33449B1 (fr) Antigènes recombinants du vrs
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
BRPI0510430A (pt) composições e métodos para vacinação mucosal
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
TN2011000353A1 (fr) Derives de thiadiazoles et d'oxadiazoles, leur preparation et leur application en therapeutique
EA200900024A1 (ru) Противогриппозная вакцина
UA100507C2 (ru) Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd)
WO2006060710A3 (fr) Preparations de vaccins destinees a une administration intradermique, contenant des adjuvants et des agents antigeniques
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
EA200701113A1 (ru) Макролиды
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire